Giovanni Stropoli, previously an executive of InterMune Inc, has joined Santhera Pharmaceuticals Holding AG as chief commercial officer. At InterMune Mr Stropoli was responsible for the launch of Esbriet, a treatment for idiopathic pulmonary fibrosis. InterMune was acquired by Roche in 2014.
Santhera has also expanded its management team with the promotion of Nicholas Coppard to head development; Günther Metz to lead business development and Oliver Strub to the position of general counsel.
Santhera announced the appointments on 30 January 2015.
Copyright 2015 Evernow Publishing Ltd